Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
In the current study we tested the hypothesis that new 0.05% Cetylpyridinium chloride (CPC)
mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX): 1) yield
similar or better clinical results regarding the inhibition of de novo plaque growth compared
to those achieved with an already marketed 0.12% CHX mouthrinse (Perio-Aid Treatment without
alcohol. Dentaid, Spain), 2) reduce the side effects caused by the marketed 0.12% CHX formula
and 3) that these mouthrinses have no negative microbiological effects, and they control
total bacterial loads.